Bone Biologics completed a privately negotiated financing, selling 2,112,677 pre-funded warrants alongside equal numbers of Series F and Series G common stock warrants at a combined $1.419 per unit. The deal closed on July 9, 2026, generating approximately $2.7 million in net proceeds, with a further ~$6 million in potential gross proceeds if the common warrants are exercised for cash. Series F and G warrants are priced at $1.42 per share and become exercisable following shareholder approval and the effectiveness of a resale registration statement, while pre-funded warrants are immediately exercisable at $0.001 per share. H.C. Wainwright served as exclusive placement agent, receiving customary cash fees, expense reimbursements, and placement agent warrants.
Agreement 1: Bone Biologics Raises $2.7 Million in Private Placement; Adds $6 Million Upside From Warrants
- Agreement type: Securities Purchase Agreement for private placement of pre-funded and common warrants
- Counterparty: Investor
- Signed / Effective: Jul 07 2026 / Jul 09 2026
- Duration / Termination: At will
- Reason: Raise capital for trials and working capital
Agreement 2: Bone Biologics Enters Registration Rights Agreement to Register Resale of Warrant Shares
- Agreement type: Registration Rights Agreement for resale registration
- Counterparty: Investor
- Signed / Effective: Jul 07 2026 / Jul 07 2026
- Duration / Termination: At will
- Reason: Enable resale liquidity for offering securities
Agreement 3: Bone Biologics Engages H.C. Wainwright as Placement Agent for July 2026 Offering
- Agreement type: Exclusive placement agency engagement for private offering
- Counterparty: H.C. Wainwright & Co.
- Signed / Effective: Jul 07 2026 / Jul 09 2026
- Duration / Termination: At will
- Reason: Arrange and place the private financing
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.